Efficacy of positive airway pressure on brain natriuretic peptide in patients with heart failure and sleep-disorder breathing: a meta-analysis of randomized controlled trials

Lung. 2015 Apr;193(2):255-60. doi: 10.1007/s00408-015-9684-z. Epub 2015 Jan 15.

Abstract

Objective: Positive airway pressure (PAP) has been recognized as an effective therapeutic option for sleep-disordered breathing (SDB) in patients with heart failure (HF), and it can improve left ventricular function. Whether PAP can ameliorate serum brain natriuretic peptide (BNP) levels, a biomarker of HF, is controversial. The purpose of the present study was to quantitatively assess the efficacy of PAP on BNP in patients with HF and SDB.

Methods: A systematic search of PubMed, Embase, Web of Science and Cochrane library identified six randomized controlled trials (RCTs), in which PAP was compared with medical therapy, subtherapeutic PAP or different types of PAP. The data of BNP were extracted and pooled into meta-analysis using STATA 12.0.

Results: Totally 6 RCT studies (7 cohorts) with 222 patients were enrolled into analysis. The quality of each study was high and the heterogeneity (I(2) = 58.1%) was noted between studies. A significant reduction of BNP was observed after PAP treatment in patients with HF and SDB (SMD -0.517, 95% CI -0.764 to -0.270, z = 4.11, p = 0.000).

Conclusion: Our meta-analysis of RCTs demonstrated that PAP elicits significant reduction of BNP in patients with HF and SDB.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Continuous Positive Airway Pressure*
  • Heart Failure / blood*
  • Heart Failure / complications
  • Heart Failure / therapy*
  • Humans
  • Natriuretic Peptide, Brain / blood*
  • Randomized Controlled Trials as Topic
  • Sleep Apnea Syndromes / blood*
  • Sleep Apnea Syndromes / complications
  • Sleep Apnea Syndromes / therapy*

Substances

  • Natriuretic Peptide, Brain